Skip to main content
Fig. 3 | BMC Rheumatology

Fig. 3

From: Efficacy and safety of upadacitinib, a selective JAK-1 inhibitor in treatment of ankylosing spondylitis: a meta-analysis

Fig. 3

Efficacy of UPA in AS patients. A, Number of AS patients with ASAS criteria in groups; B, Number of AS patients with BASDAI50 in groups; C, Number of AS patients with ASDAS LDA in groups; D, Number of AS patients with ASDAS ID in groups; E, ASDAS CRP of AS patients before and after UPA or placebo treatment; F, BASFI score of AS patients before and after UPA or placebo treatment; G, MASES score of AS patients before and after UPA or placebo treatment; H, Total back pain score of AS patients before and after UPA or placebo treatment; I, Nighttime back pain score of AS patients before and after UPA or placebo treatment; J, SPARCC MRI score of AS patients before and after UPA or placebo treatment

Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us